Relentless Innovation to Avail Breakthrough Therapies to a Global Community
XBiotech is perhaps the most dynamic Biopharmaceutical company anywhere: A cancer therapy program with two unique pivotal Phase III clinical studies involving an agent that makes patients feel better, while undermining the tumor's ability to grow, spread and do harm; Multiple indications in Phase II clinical development; A discovery pipeline of therapeutic antibodies that are safer and better tolerated than ever before; And novel manufacturing technology to reduce cost and complexity of drug development.
  • About Us

    XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

    The Company is a leading developer of biological therapies—including a pipeline of True Human™ antibodies and proven blockbuster biosimilars.

    read more
  • Partners

    Learn more about the companies we work with.

Company news

view all company news

Clinical Trials

View all current trials

  • Xilonix™ is a first-in-class True Human™ monoclonal (IgG1k) antibody that neutralizes biological activity of interleukin-1&alpha. Xilonix™ is called a True Human™ monoclonal antibody to differentiate it from other antibodies, such as so called "fully human," that are in fact not derived from a mature human antibody sequence...
  • Antibodies are the body's main defense against bacterial infection. Staphylococcus aureus (S. aureus), including methicillin resistant S. aureus (MRSA) strains, however, have specific immune evasion strategies that enable the bacteria to escape neutralization by antibodies...
  • Inflammatory skin conditions encompass a wide range of diagnoses from common conditions such as acne, eczema, and psoriasis, to more rare conditions such as pyoderma gangrenosum. One common factor unifying the pathophysiology of these conditions is...